Allovir
Allovir
ALVR
NASDAQ
0.78
USD
73.33%
About
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases.
Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV).
Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 179.9K |
| Three Month Average Volume | 6.9M |
| High Low | |
| Fifty-Two Week High | 3.315 USD |
| Fifty-Two Week Low | 0.58 USD |
| Fifty-Two Week High Date | 01 Sep 2023 |
| Fifty-Two Week Low Date | 13 May 2024 |
| Price and Volume | |
| Current Price | 0.7793 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -4.20% |
| Thirteen Week Relative Price Change | -3.55% |
| Twenty-Six Week Relative Price Change | -5.25% |
| Fifty-Two Week Relative Price Change | -80.13% |
| Year-to-Date Relative Price Change | -3.19% |
| Price Change | |
| One Day Price Change | 0.62% |
| Thirteen Week Price Change | 3.23% |
| Twenty-Six Week Price Change | 4.18% |
| Five Day Price Change | 3.91% |
| Fifty-Two Week Price Change | -75.10% |
| Year-to-Date Price Change | 14.64% |
| Month-to-Date Price Change | 5.17% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.27706 USD |
| Book Value Per Share (Most Recent Quarter) | 1.04318 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.27706 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.04318 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.05411 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.82994 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.2285 USD |
| Normalized (Last Fiscal Year) | -1.71394 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.82994 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.2285 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.82994 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.2285 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.61136 USD |
| Cash Per Share (Most Recent Quarter) | 1.12401 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.82609 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.22401 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.05623 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -275,387 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -378,240.60% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -387,230.90% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -378,613.90% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 32.56% |
| Tangible Book Value (5 Year) | 46.53% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 88.97% |
| EPS Change (Trailing Twelve Months) | 32.69% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -129,612,000 |
| Net Debt (Last Fiscal Year) | -183,943,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 7 |
| Current Ratio (Most Recent Quarter) | 55 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -124,451,000 |
| Free Cash Flow (Trailing Twelve Months) | -120,910,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -81.40% |
| Return on Assets (Trailing Twelve Months) | -67.85% |
| Return on Assets (5 Year) | -52.85% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -102.85% |
| Return on Equity (Trailing Twelve Months) | -80.33% |
| Return on Equity (5 Year) | -77.23% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -91.73% |
| Return on Investment (Trailing Twelve Months) | -73.72% |
| Return on Investment (5 Year) | -57.72% |